{"id":53616,"date":"2026-03-30T13:16:35","date_gmt":"2026-03-30T13:16:35","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=53616"},"modified":"2026-04-01T17:52:02","modified_gmt":"2026-04-01T17:52:02","slug":"2026-leap-workshop-recordings-and-presentations-online","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/53616","title":{"rendered":"LEAP pre-CROI workshop 2026: recordings and presentations online"},"content":{"rendered":"

Simon Collins, HIV i-Base<\/strong><\/p>\n

Every year for the last ten years the LEAP research programme into long-acting and extended release (LA\/ER) drugs for HIV, TB, hepatitis and other infections holds an investigator workshop just before CROI. [1]<\/strong><\/p>\n

Although these meetings of invited doctors, researchers, drug companies, donors, regulators and community advocates are closed, the presentations are posted open access shortly after the meeting.<\/p>\n

The workshop included important opening plenaries on global access, including for people who use drugs and children and adolescents.<\/p>\n

Recordings are hyperlinked from the programme below.<\/p>\n

Welcome<\/a>
\nCarl Dieffenbach, Senior Advisor to the Office of the Director, Fogarty International Center<\/p>\n

Overview of workshop<\/a>
\nCharles Flexner, Director LEAP, Johns Hopkins University<\/p>\n

Plenary 1 \u2013 Access<\/strong>
\nChair: Elaine Abrams, Columbia University<\/p>\n

Global Access to Long-Acting Formulations for HIV: A Country Perspective<\/a>
\nFrancois Venter, Ezintsha<\/p>\n

Considerations for the Development of Long-Acting Formulations for People Who Use Drugs<\/a>
\nSunil Solomon, Johns Hopkins University<\/p>\n

Availability of LA Products for Children and Adolescents: When?<\/a>
\nMoherndran Archary, University of Kwazulu-Natal<\/p>\n

Global Access to Long-Acting Formulations for HIV: A Community Perspective<\/a>
\nImelda Mahaka, Pangea Zimbabwe AIDS Trust
\nRonald Ssenyonga, Makerere University
\nPanel Moderator: Paul Domanico, Clinton Health Access Initiative<\/p>\n

Focus Group 1 Report-Back<\/strong>
\nBest Practices for Managing HIV\/HBV Coinfection in Those Starting or Switching to LA HIV Treatment<\/a>
\nChair: Chloe Thio, JHU
\nCo-Chair: Jordan Feld, UHN Research
\nRapporteur: Monica Gandhi, UCSF<\/p>\n

Panel and group discussion<\/a><\/p>\n

Plenary 2 \u2013 Products
\n<\/strong>Chair: Paul Domanico, Clinton Health Access Initiative<\/p>\n

Preclinical Development of Long-Acting Anti-Infective Drugs and Formulations Supported by NIH<\/a>
\nRoger Ptak, NIH<\/p>\n

Long-Acting Injectable Agents as Tools to End TB: An Overview of Activities Supported by the Gates Medical Research Institute<\/a>
\nChris Vinnard, Gates Medical Research Institute<\/p>\n

LONGEVITY Formulation Development for HCV and TB\u00a0<\/a>
\nDavid Thomas, Johns Hopkins University<\/p>\n

All-in-one LA-TLD product for HIV treatment reached IND status<\/a>
\nRodney Ho, University of Washington<\/p>\n

(Part 1 – Supporting Perspective)
\n<\/strong>Broadly Neutralizing Monoclonal Antibodies for HIV Treatment and Prevention: Why We Should Be Excited<\/a>
\nHuub Gelderblom, HIV Vaccine Trials Network<\/p>\n

(Part 2 – Counter-Perspective)
\n<\/strong>Broadly Neutralizing Monoclonal Antibodies for HIV Treatment and Prevention: Why We Should Be Cautious<\/a>
\nDaniel Kuritzkes, Harvard University<\/p>\n

Rebuttals and Discussion<\/a>
\nALL<\/strong><\/p>\n

Plenary 3 \u2013 Products
\n<\/strong>Chair: Kimberly Scarsi, University of Nebraska Medical Center<\/p>\n

Current Status of the ViiV LA\/ER Pipeline<\/a>
\nLionel Tan, ViiV Healthcare | Alex Rinehart, ViiV Healthcare<\/p>\n

Current Status of the Merck LA\/ER Pipeline<\/a>
\nLuisa Stamm, Merck<\/p>\n

Current Status of the Gilead LA\/ER Pipeline<\/a>
\nMoupali Das and\u00a0Martin Rhee, Gilead Sciences<\/p>\n

Current Status of the J&J Tuberculosis LA\/ER Pipeline<\/a>
\nVivian Cox, Johnson & Johnson<\/p>\n

Focus Group 2 Report-Back:<\/strong>
\nBest Practices for Managing HIV\/HBV Coinfection in Those Starting or Switching to LA HIV Treatment<\/a>
\nChair: Brian Kearney, Exavir Therapeutics
\nCo-Chair: Paul Domanico, CHAI
\nRapporteur: Keith Crawford, NIH<\/p>\n

Industry Roundtable<\/a>
\nViiV, Merck, Gilead, J&J & Generic Representatives<\/p>\n

Plenary 4 \u2013 Implementation
\n<\/strong>Chair: David Thomas, Johns Hopkins University<\/p>\n

Focus Group 3 Report-Back:
\nEnding the HIV Epidemic\u2014Is Lenacapavir the Answer?<\/a>
\nChair: Sinead Delany-Moretlwe, Wits RHI
\nCo-Chair: Angela Colbers, Radboud UMC
\nRapporteur: Ethel Weld, JHU<\/p>\n

What Is Implementation Science, and What Is Its Role in the NIH Research Portfolio?<\/a>
\nGeri Donenberg, NIH<\/p>\n

The New PEPFAR: Implications for LA Treatment and Prevention<\/a>
\nMike Reid, PEPFAR<\/p>\n

Introduction to the LEAP User Preferences Core\u00a0<\/a>
\nJos\u00e9 Bauermeister, University of Pennsylvania<\/p>\n

Focus Group 4 Report-Back:<\/strong>
\nUser Preferences Research\u2014Specific Aims and Strategic Plans<\/a>
\nChair: Jos\u00e9 Bauermeister
\nCo-Chair: Rachel Bender Ignacio
\nRapporteur: Karine Dub\u00e9<\/p>\n

Reference<\/p>\n

    \n
  1. Long-Acting\/Extended Release (LA\/ER) Antiretroviral Research Resource Program (LEAP) Investigator Meeting and Annual Workshop. 21 February 2026, Denver, Colorado.
    \n    https:\/\/longactinghiv.org\/content\/LEAP_Workshop_2026<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base Every year for the last ten years the LEAP research programme into long-acting and extended release (LA\/ER) drugs for HIV, TB, hepatitis and other infections holds an investigator workshop just before CROI. [1] Although these meetings …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3],"tags":[346],"class_list":["post-53616","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-antiretrovirals","tag-croi-2026"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/53616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=53616"}],"version-history":[{"count":3,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/53616\/revisions"}],"predecessor-version":[{"id":53636,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/53616\/revisions\/53636"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=53616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=53616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=53616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}